Vitamin D3 Treatment and Homocysteine Concentrations Among Overweight Reproductive Women

Vitamin D3 Treatment Decreases Serum Total Homocysteine Concentrations of Overweight Reproductive Women: Randomized Placebo Controlled Clinical Trail

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT03310307

Enrollment

100

Registered

2017-10-16

Start date

2016-04-01

Completion date

2016-10-30

Last updated

2017-10-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Homocystinaemia, Vitamin D Deficiency

Keywords

Homocysteine, Overweight, vitamin D3, Reproductive women, RCT

Brief summary

100 overweight reproductive vitamin D deficient women were divided into two groups; vitamin D (n = 50) and placebo (n = 50). Vitamin D group received treatment dose of 50,000 IU of vitamin D3 per week for 2 consecutive months and placebo group received placebo tablets similar in size, shape and color to vitamin D3 for 2 months also. Total homocysteine concentrations were measured before intervention (basal), on 30 days (one month) and on 60 days (2 months) of intervention. Changes in means of homocysteine concentrations for placebo and vitamin D group over time showed significant difference on 30 and 60 days of intervention. Mean comparisons of homocysteine concentrations and standard error of the means before and after intervention showed statistical significant decrease in homocysteine concentrations among vitamin D group.

Interventions

DRUGVit D

50,000 IU

OTHERPlacebo

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking description

Double blind

Eligibility

Sex/Gender

FEMALE

Age

18 Years to 49 Years

Healthy volunteers

Yes

Inclusion criteria

* Overweight (BMI between 25-29.99 kg/m2) * Had 25(OH)D \< 20 ng/mL * Had normal vitamin B-12 and folic acid levels * Not diagnosed with any chronic diseases * Agreed to participat in the study

Exclusion criteria

* age \< 18 or \> 49 years * BMI \> 30 kg/m2 or \< 25 kg/m2 * 25 (OH)D level \> 20 ng/ml * tHcy levels greater than 100 µmol/L * Abnormal vitamin B-12 or folic acid levels * Chronic diseases * Pregnant or lactating

Design outcomes

Primary

Measure	Time frame	Description
25(OH)D3	2 months	vitamin D in serum

Secondary

Measure	Time frame	Description
Homocysteine	2 months	serum total homocysteine

Countries

Jordan

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 6, 2026